WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)

被引：0
|
作者：
Berenson, J. [1 ]
Cartmell, A. [2 ]
Lyons, R. [3 ,4 ]
Harb, W. [5 ]
Tzachanis, D. [6 ]
Agajanian, R. [7 ]
Boccia, R. [8 ]
Coleman, M. [9 ]
Moss, R. A. [10 ]
Rifkin, R. M. [11 ,12 ]
Schupp, M. [13 ]
Dixon, S. [13 ]
Ou, Y. [13 ]
Anderl, J. [13 ]
Berdeja, J. [14 ]
机构：
[1] Inst Myeloma & Bone Canc Res, Los Angeles, CA USA
[2] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[3] US Oncol Res Ctr South Texas, San Antonio, TX USA
[4] US Canc Care Ctr South Texas, San Antonio, TX USA
[5] Horizon Oncol Ctr, Lafayette, IN USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Oncol Inst Hope & Innovat, Downey, CA USA
[8] Ctr Canc & Blood Disorders, Bethesda, MD USA
[9] NewYork Presbyterian Weill Cornell, New York, NY USA
[10] Robert A Moss MD Inc, Fountain Valley, CA USA
[11] US Oncol Res Canc Ctr, Denver, CO USA
[12] US Rocky Mt Canc Ctr, Denver, CO USA
[13] Amgen Inc, Thousand Oaks, CA USA
[14] Sarah Cannon Res Inst, Nashville, TN USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P661
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [31] Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Nam, Jennifer
    Severson, Erica
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd
    Karrison, Theodore
    Zonder, Jeffrey
    BLOOD, 2016, 128 (22)
  • [32] A PHASE 1-2 STUDY OF CARFILZOMIB-POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE
    Bringhen, S.
    Mina, R.
    Liberati, A. M.
    Belotti, A.
    Gaidano, G.
    Bertazzoni, P.
    Stocchi, R.
    Ruggeri, M.
    Ribolla, R.
    Di Sano, C.
    Patriarca, F.
    Bernardini, A.
    De Paoli, L.
    Cafro, A. M.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    HAEMATOLOGICA, 2017, 102 : 25 - 25
  • [33] Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lipe, Brea
    Tuchman, Sascha
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Baljevic, Muhamed
    Rossi, Adriana C.
    Bahlis, Nizar J.
    White, Darell
    Chen, Christine
    Sutherland, Heather J.
    Kotb, Rami
    LeBlanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William
    Sheehan, Heidi
    Ju, Yawen
    Kai, Kazuharu
    Schiller, Gary J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [35] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [36] Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
    Chari, Ajai
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chhabra, Saurabh
    Girnius, Saulius
    Shustik, Chaim
    Stuart, Robert
    Lee, Yihua
    Salman, Zeena
    Liu, Emily
    Valent, Jason
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 353 - 362
  • [37] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
    Derman, Benjamin A.
    Zonder, Jeffrey
    Reece, Donna
    Cole, Craig
    Berdeja, Jesus
    Stefka, Andrew T.
    Major, Ajay
    Kin, Andrew
    Griffith, Kent
    Jasielec, Jagoda
    Jakubowiak, Andrzej J.
    BLOOD ADVANCES, 2023, 7 (19) : 5703 - 5712
  • [38] CARFILZOMIB AND DEXAMETHASONE VS SUBCUTANEOUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SECONDARY ANALYSIS FROM THE PHASE 3 STUDY ENDEAVOR (NCT01568866)
    Goldschmidt, H.
    Moreau, P.
    Palumbo, A.
    Joshua, U.
    Pour, L.
    Hajek, R.
    Facon, T.
    Ludwig, H.
    Niesvizky, R.
    Oriol, A.
    Rosinol, L.
    Straub, J.
    Suvorov, A.
    Araujo, C.
    Rimashevskaya, E.
    Pika, T.
    Gaidano, G.
    Weisel, K.
    Goronova-Marinova, V.
    Schwarer, A.
    Minuk, L.
    Masszi, T.
    Karamanesht, I.
    Offidani, M.
    Hungria, V.
    Spencer, A.
    Orlowski, R.
    Iskander, K.
    Feng, S.
    Aggarwal, S.
    Chng, W. J.
    Dimopoulos, Ma
    HAEMATOLOGICA, 2016, 101 : 260 - 261
  • [39] Carfilzomib (30 min infusion) with and without dexamethasone in patients with relapsed and/or refractory multiple myeloma: Results from the phase 1b study PX-171-007 (NCT00531284)
    Badros, A. Z.
    Papadopoulos, K. P.
    Zojwalla, N.
    Lee, J. R.
    Siegel, D. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 18 - 18
  • [40] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
    Usmani, Saad Z.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David
    Weisel, Katja
    Gavriatopoulou, Maria
    Oriol, Albert
    Rabin, Neil
    Nooka, Ajay
    Qi, Ming
    Beksac, Meral
    Jakubowiak, Andrzej
    Ding, Bifeng
    Zahlten-Kumeli, Anita
    Yusuf, Akeem
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2022, 23 (01): : 65 - 76
12345